Recurrent infantile myofibromatosis: a report of conservative management and discussion of treatment strategies.
Infantile myofibromatosis is a rare proliferative mesenchymal disorder that has a potential for rapid growth and recurrence. Approximately 30% of infantile myofibromatosis lesions present in the head and neck, and some of these can cause significant morbidity. We report a case of recurrent infantile myofibromatosis that persisted after surgery and chemotherapy and was managed conservatively. Treatment of infantile myofibromatosis varies according to the size, location, and extent of disease. Solitary lesions may be simply observed in view of their potential for regression, but surgical excision, radiotherapy, and/or chemotherapy should be considered on a case-by-case basis, especially for nonresectable, rapidly progressive, or symptomatic lesions.
Ebert
Charles S
CS
Department of Otolaryngology-Head and Neck Surgery, University of North Carolina, Chapel Hill, NC 27599-7070, USA. cebert@med.unc.edu
Zdanski
Carlton
C
Ardeshirpour
Farhad
F
Patel
Mihir
M
Hart
Craig F
CF
Drake
Amelia F
AF
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D019653:Myeloablative Agonists / Q000627:therapeutic use; D018224:Myofibromatosis / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D012074:Remission Induction; D014750:Vincristine / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000972:Antineoplastic Agents, Phytogenic; D019653:Myeloablative Agonists; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide